NCT00186875View on ClinicalTrials.gov

Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

47

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Acute Lymphoblastic LeukemiaLymphoma, Lymphoblastic

Interventions

DRUG

Etoposide, cytarabine, vincristine, dexamethasone

See Detailed Description section for details of treatment interventions.

DRUG

methotrexate, teniposide, PEG-asparaginase

See Detailed Description section for details of treatment interventions.

DRUG

mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine

See Detailed Description section for details of treatment interventions.

DRUG

L-asparaginase, erwinia asparaginase

See Detailed Description section for details of treatment interventions.

PROCEDURE

chemotherapy, intrathecal chemotherapy, steroid therapy

See Detailed Description section for details of treatment interventions.

PROCEDURE

Hematopoietic Stem Cell Transplant

See Detailed Description section for details of treatment interventions.

PROCEDURE

Natural Killer (NK) Cell Transplant

See Detailed Description section for details of treatment interventions.

Trial Locations (2)

38105

St. Jude Children's Research Hospital, Memphis

92123

Rady Children's Hospital and Health Center, San Diego

All Listed Sponsors

lead

St. Jude Children's Research Hospital

OTHER

NCT00186875 - Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter